Cargando…
New frontiers in the medical management of gastrointestinal stromal tumours
The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line medical therapies are represented by the TKIs sunitinib and regorafenib, respectively. While imatinib remains the cardina...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535752/ https://www.ncbi.nlm.nih.gov/pubmed/31205499 http://dx.doi.org/10.1177/1758835919841946 |
_version_ | 1783421622887120896 |
---|---|
author | Mazzocca, Alessandro Napolitano, Andrea Silletta, Marianna Spalato Ceruso, Mariella Santini, Daniele Tonini, Giuseppe Vincenzi, Bruno |
author_facet | Mazzocca, Alessandro Napolitano, Andrea Silletta, Marianna Spalato Ceruso, Mariella Santini, Daniele Tonini, Giuseppe Vincenzi, Bruno |
author_sort | Mazzocca, Alessandro |
collection | PubMed |
description | The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line medical therapies are represented by the TKIs sunitinib and regorafenib, respectively. While imatinib remains the cardinal drug for patients with GISTs, novel therapies are being developed and clinically tested to overcome the mechanisms of resistance after treatments with the approved TKI, or to treat subsets of GISTs driven by rarer molecular events. Here, we review the therapy of GISTs, with a particular focus on the newest drugs in advanced phases of clinical testing that might soon change the current therapeutic algorithm. |
format | Online Article Text |
id | pubmed-6535752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-65357522019-06-14 New frontiers in the medical management of gastrointestinal stromal tumours Mazzocca, Alessandro Napolitano, Andrea Silletta, Marianna Spalato Ceruso, Mariella Santini, Daniele Tonini, Giuseppe Vincenzi, Bruno Ther Adv Med Oncol Review The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line medical therapies are represented by the TKIs sunitinib and regorafenib, respectively. While imatinib remains the cardinal drug for patients with GISTs, novel therapies are being developed and clinically tested to overcome the mechanisms of resistance after treatments with the approved TKI, or to treat subsets of GISTs driven by rarer molecular events. Here, we review the therapy of GISTs, with a particular focus on the newest drugs in advanced phases of clinical testing that might soon change the current therapeutic algorithm. SAGE Publications 2019-05-17 /pmc/articles/PMC6535752/ /pubmed/31205499 http://dx.doi.org/10.1177/1758835919841946 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Mazzocca, Alessandro Napolitano, Andrea Silletta, Marianna Spalato Ceruso, Mariella Santini, Daniele Tonini, Giuseppe Vincenzi, Bruno New frontiers in the medical management of gastrointestinal stromal tumours |
title | New frontiers in the medical management of gastrointestinal stromal tumours |
title_full | New frontiers in the medical management of gastrointestinal stromal tumours |
title_fullStr | New frontiers in the medical management of gastrointestinal stromal tumours |
title_full_unstemmed | New frontiers in the medical management of gastrointestinal stromal tumours |
title_short | New frontiers in the medical management of gastrointestinal stromal tumours |
title_sort | new frontiers in the medical management of gastrointestinal stromal tumours |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535752/ https://www.ncbi.nlm.nih.gov/pubmed/31205499 http://dx.doi.org/10.1177/1758835919841946 |
work_keys_str_mv | AT mazzoccaalessandro newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours AT napolitanoandrea newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours AT sillettamarianna newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours AT spalatocerusomariella newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours AT santinidaniele newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours AT toninigiuseppe newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours AT vincenzibruno newfrontiersinthemedicalmanagementofgastrointestinalstromaltumours |